INC. (NASDAQ:INCR) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearItem 5.03
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On September 18, 2018, Brain Scientific Inc., f/k/a All Soft Gels Inc. (the “Company”), filed Amended and Restated Articles of Incorporation (the “Articles”) with the Secretary of State of the State of Nevada to effect the following actions:
1.To change the name of the Company from All Soft Gels Inc. to Brain Scientific Inc.;
2.To increase the Company’s authorized shares of common stock from 50,000,000 to 200,000,000; and
3.To create and authorize 10,000,000 shares of “blank check” preferred stock.
The foregoing description of the Articles are not complete and are subject to, and qualified in its entirety by, the full text of the Articles, which are attached to this Current Report on Form 8-K as Exhibit 3.1, the terms of which are incorporated herein by reference.
|
Item 9.01 |
Financial Statements and Exhibits. |
|
Exhibit |
Description |
|
3.1 |
Amended and Restated Articles of Incorporation |
All Soft Gels Inc ExhibitEX-3.1 2 ex_124409.htm EXHIBIT 3.1 ex_124409.htm Exhibit 3.1 BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City,…To view the full exhibit click here
About INC. (NASDAQ:INCR)
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.